Company intelligence / Profile preview

GENNVAX

Seongnam, Gyeonggi-do, South Korea

Ownership: Private
Development stage: Other

Overview

Gennvax is a South Korean biotechnology company specializing in the development of therapeutic DNA vaccines for cancer and infectious diseases. As a subsidiary of GemVax & KAEL, the company utilizes a proprietary DNA vaccine platform designed to stimulate robust cellular immune responses against specific viral and tumor antigens. Its lead candidate, GV-p100, is a DNA vaccine targeting HPV-associated malignancies and is currently in clinical development for cervical cancer. The company's pipeline also includes GV-p200 for chronic Hepatitis B and research programs for other viral infections like COVID-19. Gennvax focuses on integrating genomic technology with immunotherapy to provide novel treatment options for chronic viral diseases and oncology.

Therapeutic areas: OncologyInfectious Diseases
Modalities: DNA vaccineBiologicVaccineImmunotherapy
Industry: Biotech

Partnerships

GemVax & KAEL

Beyond the preview

Go deeper on GENNVAX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GENNVAX.

Explore the full profile